Format

Send to

Choose Destination
Cancer. 2015 Aug 1;121(15):2618-26. doi: 10.1002/cncr.29404. Epub 2015 Apr 15.

Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40.

Author information

1
Section of Pathology, Oncology, and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, Italy.
2
Section of Hematology, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy.
3
Section of Microbiology, Schools of Medicine and Sciences, University of Ferrara, Ferrara, Italy.
4
Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste Italy, and University of Trieste, Trieste, Italy.
5
Hospital Headquarter Department, State Hospital, Institute for Social Security, San Marino, Republic of San Marino.
6
Department of Medical Sciences, School of Medicine, University of Trieste, Trieste, Italy.
7
Department of Surgery, School of Medicine, University of Verona, Verona, Italy.
8
Department of Medicine, School of Medicine, University of Verona, Verona, Italy.

Abstract

BACKGROUND:

Non-Hodgkin lymphoma (NHL), the most common cancer of the lymphatic system, is of unknown etiology. The identification of etiologic factors in the onset of NHL is a key event that could facilitate the prevention and cure of this malignancy. Simian virus 40 (SV40) has been considered an oncogenic agent in the onset/progression of NHL.

METHODS:

In this study, an indirect enzyme-linked immunosorbent assay with 2 synthetic peptides that mimic SV40 antigens of viral capsid proteins 1 to 3 was employed to detect specific antibodies against SV40. Serum samples were taken from 2 distinct cohorts of NHL-affected patients (NHL1 [n = 89] and NHL2 [n = 61]) along with controls represented by oncologic patients affected by breast cancer (BC; n = 78) and undifferentiated nasopharyngeal carcinoma (UNPC; n = 64) and 3 different cohorts of healthy subjects (HSs; HS1 [n = 130], HS2 [n = 83], and HS3 [n = 87]).

RESULTS:

Immunologic data indicated that in serum samples from NHL patients, antibodies against SV40 mimotopes were detectable with a prevalence of 40% in NHL1 patients and with a prevalence of 43% in NHL2 patients. In HSs of the same median age as NHL patients, the prevalence was 16% for the HS1 group (57 years) and 14% for the HS2 group (65 years). The difference was statistically significant (P < .0001 and P < .001). Interestingly, the difference between NHL1/NHL2 patients and BC patients (40%/43% vs 15%, P < .001) and between NHL1/NHL2 patients and UNPC patients (40%/43% vs 25%, P < .05) was significant.

CONCLUSIONS:

Our data indicate a strong association between NHL and SV40 and thus a need for innovative therapeutic approaches for this hematologic malignancy.

KEYWORDS:

NHL; SV40; antibody; immunology; serum

PMID:
25877010
DOI:
10.1002/cncr.29404
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center